Álvaro Juárez Soto, MD, discusses the efficacy of apalutamide plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.
Álvaro Juárez Soto, MD, the chief of Urology Service at Hospital Universitario de Jerez, Cádiz, Spain, discusses the efficacy of apalutamide (Erleada) plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer, as demonstrated in the phase 3 TITAN trial (NCT02489318).
Several key findings emerged from the TITAN trial, according to Juárez Soto. The study demonstrated the real-world effects of apalutamide vs placebo in terms of overall survival (OS), he explains. The OS at 24 months was 82.4% in the apalutamide cohort. The group also had a radiographic progression-free survival (PFS) of 68%, which translated to a 52% reduction in risk of radiographic PFS or death. Both measurements were the co-primary end points of the study, Juárez Soto concludes.